NRC Health Targets Margin Recovery and Disciplined CapEx Following Strong Q1 Performance

NRC Health has signaled a strategic pivot toward margin expansion and capital discipline following a robust start to the 2026 fiscal year. CEO Trent Green reported strong sales and adjusted EBITDA performance for the first quarter, indicating a positive trajectory for the company's operational health. A primary driver of this growth is the company's Total Recurring Contract Value (TRCV), which reached an all-time high of $152 million. This represents a 13% increase compared to the same period last year, highlighting strong client retention and successful new sales initiatives. Management has now outlined a clear path to restore EBITDA margins to the low-30% range. To support this efficiency drive and ensure sustainable growth, the company is targeting a disciplined quarterly capital expenditure (CapEx) budget of between $1 million and $1.5 million. The focus on recurring revenue and margin recovery suggests a transition from aggressive growth toward operational optimization. Investors will likely monitor whether the company can hit these specific margin targets while maintaining its current sales momentum in the healthcare sector.